1. Clinical Overview
A fixed-dose combination of two methylxanthine derivatives with bronchodilator, anti-inflammatory, and mucolytic properties, used primarily for the management of chronic obstructive pulmonary disease (COPD) and bronchial asthma. Doxofylline is a selective phosphodiesterase-4 (PDE-4) inhibitor, while Acebrophylline is a mucoregulator and bronchodilator. This combination offers synergistic action for improved airway clearance and reduced bronchospasm with a potentially better safety profile regarding cardiac and CNS stimulation compared to theophylline.
| Onset | Duration | Bioavailability |
|---|---|---|
| Doxofylline: 1-2 hours; Acebrophylline: 30-60 minutes. | Doxofylline: Approximately 12 hours; Acebrophylline: Approximately 8-10 hours. | Doxofylline: ~62-75%; Acebrophylline: ~70-80%. |
2. Mechanism of Action
The combination exerts a dual action: 1) Doxofylline selectively inhibits phosphodiesterase-4 (PDE-4), increasing intracellular cAMP in bronchial smooth muscle and inflammatory cells, leading to bronchodilation and anti-inflammatory effects (reduced TNF-α, IL-8). 2) Acebrophylline is a prodrug that releases Ambroxol (a mucolytic) and Theophylline-7-acetate. Ambroxol stimulates surfactant production, breaks down acid mucopolysaccharide fibers in sputum, and enhances ciliary activity. Theophylline-7-acetate contributes to bronchodilation. Together, they reduce bronchospasm, inflammation, and mucus viscosity, improving airway clearance.
3. Indications & Uses
- Chronic Obstructive Pulmonary Disease (COPD) - maintenance therapy
- Bronchial Asthma - as an add-on bronchodilator therapy
4. Dosage & Administration
Adult Dosage: One tablet (Doxofylline 400mg + Acebrophylline 100mg) twice daily, preferably after meals.
Administration: Administer orally with a full glass of water, preferably after food to minimize gastric irritation. Swallow whole; do not crush or chew. Maintain adequate hydration to aid mucolytic action.
5. Side Effects
Common side effects may include:
- Nausea
- Epigastric discomfort/Heartburn
- Headache
- Insomnia
- Mild palpitations
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Ciprofloxacin/Enoxacin | Markedly increases Doxofylline levels (CYP1A2 inhibition), risk of toxicity. | Major |
| Phenobarbital, Phenytoin, Carbamazepine | Decreases Doxofylline levels (CYP450 induction), may reduce efficacy. | Moderate |
| Warfarin | May potentiate anticoagulant effect; monitor INR. | Moderate |
| Beta-2 Agonists (Salbutamol) | Additive hypokalemic effect; monitor potassium. | Moderate |
| Diuretics (Furosemide) | Increased risk of hypokalemia and potential arrhythmias. | Moderate |
| Allopurinol | May increase Doxofylline levels. | Moderate |
| Cimetidine | May increase Doxofylline levels (weak CYP inhibition). | Minor |
7. Patient Counselling
- DO take the tablet after food with a full glass of water.
- DO maintain regular dosing intervals (every 12 hours).
- DO inform your doctor about all other medicines you are taking.
- DO keep follow-up appointments to monitor response.
- DONT crush, chew, or break the tablet.
- DONT take an extra dose if you miss one. Skip and take the next scheduled dose.
- DONT start or stop any other medication without consulting your doctor.
- DONT consume excessive caffeine (coffee, tea, energy drinks).
8. Toxicology & Storage
Overdose: Nausea, vomiting, hematemesis, tremors, agitation, insomnia, severe tachycardia, cardiac arrhythmias (supraventricular and ventricular), hypotension, seizures, metabolic acidosis, hypokalemia, hyperglycemia. Can be fatal.
Storage: Store below 30°C, in a cool, dry place, protected from light and moisture. Keep out of reach of children.